This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

MDCO-216

The Medicines Company

Drug Names(s): ETC-216, AIM, apolipoprotein A-I Milano (ApoA-I Milano)/phospholipid complex

Description: ETC-216 is an intravenous synthetic variant of high-density lipoprotein (HDL). HDL is the good cholesterol that removes excess cholesterol and other lipids from artery walls and other tissues.

Deal Structure: Esperion Drug acquired via merger with Pfizer in 2004.

In December 2009, The Medicines Company announced the exclusive worldwide licensing of ApoA-I Milano from Pfizer.

Under the terms of the agreement, Pfizer will receive an up-front payment of $10 million for ApoA-I Milano and will receive additional payments upon the achievement of certain clinical, regulatory and sales milestones up to a total of $410 million:

  • up to $20 million during development,
  • up to $90 million upon filing and approval,
  • $50 million for annual sales over $500 million,
  • $100 million for annual sales over $1 billion,
  • $150 million for annual sales over $1.5 billion.

Pfizer will also be eligible to receive single-digit royalty payments on worldwide net sales of ApoA-I Milano. The Medicines Company will also pay $7.5 million to third parties.

Partners: Pfizer Inc.


MDCO-216 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug